



Background

- The EPA is moving towards cost effective and efficient methods for characterizing chemical hazard for risk assessment.
- Our lab uses a battery of cell-based assays to identify and characterize developmental neurotoxicity (DNT) hazard.
- These phenotypic assays evaluate chemical effects on key neurodevelopmental processes.



Objective:
Characterize the presence of important neurodevelopmental signaling pathways in our *in vitro* assay battery using specific chemical pathway modulators.

Methods




Pathway	Compound		Concentration	Chemical																						
	Activator	Inhibitor		BMPR	Notch	EGFR	Wnt	PPAR-γ	COX-2	mTORC	PDGFR	PKC	RHO	EP1-4	CREB	AKT	ETC I	EGFR	NO-cGMP	ROCK	Protein	HDAC	PARP1	ERK/MAPK	p38/MAPK	
BMPR	BMP2	BMP7	2.5µg/mL																							
Notch	DAPT		1nM - 30µM																							
EGFR	PD153035	AG1478	0.3nM - 10µM																							
Wnt	CHIR99021	IWP2	0.8nM - 25µM																							
PPAR-γ	Pioglitazone		1nM - 30µM																							
COX-2	Celecoxib		1nM - 30µM																							
mTORC	MHY1485	Rapamycin	1nM - 30µM																							
AKT	MK-2206		1nM - 30µM																							
PDGFR	CP-673451		0.3nM - 10µM																							
PKC	BIS-1/BIM-1		1nM - 30µM																							
RHO	Narciclasine		1nM - 30µM																							
EP1-4	PGE2		1nM - 30µM																							
CREB	KG-501		1nM - 30µM																							
ETC I	Rotenone		0.01nM - 1µM																							
NO-cGMP	ODQ		1nM - 30µM																							
ROCK	Y27632		1nM - 30µM																							
Protein Syn.	Cycloheximide		1nM - 30µM																							
HDAC	Vorinostat		1nM - 30µM																							
PARP1	Talazoparib		0.3nM - 10µM																							
ERK/MAPK	SCH722984		1nM - 30µM																							

Work in progress
Evaluated qualitatively while awaiting quantitative analysis in ToxCast.

Assay	BMPR	Notch	EGFR	Wnt	PPAR-γ	COX-2	mTORC	PDGFR	PKC	RHO	EP1-4	CREB	AKT	ETC I	EGFR	NO-cGMP	ROCK	Protein	HDAC	PARP1	ERK/MAPK	p38/MAPK			
hNP1 Apoptosis	10							11																	
hNP1 Proliferation																									
h. Neurite Outgrowth			1					2																	
r. Neurite Outgrowth			4			6	3	5																	
Cortical Synap.																									
Network Formation	7	8									9														

Active Selective
Active/Cytotoxic
Inactive
Awaiting Data
To be tested


*Numbers correspond to figures below



Preliminary ToxCast Analysis

- The current NOG data (15 chemicals) has been analyzed using ToxCast R package tcplfit2 (v0.1.6). The computed AC₅₀ for each chemical and endpoint is given in the figure below.
- The color scale indicates selectivity, which is determined as the ratio between the cytotoxic AC₅₀ and the AC₅₀ for the endpoint of interest.

$$\text{Selectivity Ratio} = \frac{AC_{50}^{Cyto}}{AC_{50}^{Endpoint}} \geq 3, \text{ Selective Effect}$$



- Eventually, the AC₅₀ for each chemical and endpoint in the DNT battery will be computed, showing which pathways are best covered by the DNT battery and where improvements are needed.

Conclusions

- The DNT battery captures some important and highly conserved signaling pathways associated with various processes involved in neurodevelopment.
- Specifically, we demonstrated that:
 - Wnt, mTORC, PKC, and PDGFR pathway modulators have selective effects on neurite outgrowth.
 - ERK1/2, AKT, and COX-2 pathway modulators demonstrated non-selective effects on neurite outgrowth.
- To date, ROCK, NO-cGMP, and COX-2 do not seem to play a significant role in our assays.

Future Directions:

- Ten chemicals remain to be tested in the battery.
- After all chemicals have been tested, a concentration-response analysis will be performed using the ToxCast pipeline.
- If we find that developmentally relevant biology is not being adequately recapitulated in the battery, we may explore incorporating other assays that include these pathways.

Discussion

- These results work in conjunction with the full OECD DNT battery developed in collaboration with global partners.
- Our work expands upon previous *in vitro* DNT pathway characterizations especially when it comes to neurite outgrowth¹, demonstrating that our battery is sensitive to Wnt, PKC, PDGFR, and mTORC disruption.
- A more robust characterization of the biology captured by our assays will aid in the interpretation of results gathered using the DNT battery.

References

- Masjosthusmann, Jonathan Blum, Kristina Bartmann, Xenia Dolde, Anna-Katharina Holzer, Lynn-Christin Stürz, Eike Hagen Keßel, et al. "Establishment of an *In-Vitro* Testing Battery for the Assessment of Developmental Neurotoxicity." *Efsa Supporting Publications* 17, no. 10 (October 2020). <https://doi.org/10.2903/sp.efsa.2020.EN-1938>.
- Harrill, Joshua A., Theresa Freudenrich, Kathleen Wallace, Kenneth Ball, Timothy J. Shafer, and William R. Mundy. "Testing for Developmental Neurotoxicity Using a Battery of *In-Vitro* Assays for Key Cellular Events in Neurodevelopment." *Toxicology and Applied Pharmacology* 354 (September 2018): 24–39. <https://doi.org/10.1016/j.taap.2018.04.001>.
- Johnstone, Andrew F.M., Guenter W. Gross, Dieter G. Weiss, Olaf H.-U. Schroeder, Alexandra Gramowski, and Timothy J. Shafer. "Microelectrode Arrays: A Physiologically Based Neurotoxicity Testing Platform for the 21st Century." *Neuro Toxicology* 33, no. 4 (August 2010): 331–50. <https://doi.org/10.1016/j.neuro.2010.04.001>.
- Some images made with the help of BioRender.com assets

*The views expressed in this poster are those of the author(s) and do not necessarily represent the views or policies of the U.S. Environmental Protection Agency.